We have specially designed this preset colorectal cancer organoid panel to meet the growing demands for a cost-effective and clinically-relevant solution for drug screening and development.
Leverage our extensive body of knowledge in intestinal biology and superior models to translate your preclinical data to the clinic.
HUB Organoids can be developed from patients currently enrolled in clinical trials and dosed in parallel to the patient population with identical protocols to rapidly:
NEWS AND INSIGHTS